The Medical Data Market in 2026: Who Owns It, Who Sells It, and Where AI Fits

The medical data market is large, fragmented, and easy to misread. Most people picture "one big pile of health records," but in practice the landscape is a stack of distinct asset classes — each with its own owners, access models, strengths, and blind spots. This guide maps that landscape from first principles, then shows where AI changes the demand curve and where a real gap remains.

What "the medical data market" actually refers to

When buyers say "medical data," they usually mean one of several very different things. Clinical narratives in an electronic health record (EHR) are not the same asset as a billing claim, which is not the same as a peer-reviewed academic cohort, which is not the same as a machine-generated synthetic table. They differ in who captures them, what they capture well, how they are governed, and what you are legally allowed to do with them.

A useful mental model: health data is captured for a primary purpose (treating a patient, getting paid, running a study) and then, where law and consent allow, made available for a secondary purpose (research, analytics, model development). The "market" is really the set of mechanisms — licensing, governed access, de-identification, tokenized linkage — that move data from primary to secondary use without breaking privacy law.

> This article is a market overview, not legal or compliance advice. De-identification standards (for example, HIPAA's Safe Harbor and Expert Determination methods in the U.S.) and permitted uses vary by jurisdiction and contract. Confirm requirements with qualified counsel.

The asset classes: EHR, claims, registries, academic, and synthetic

EHR / clinical data. Generated at the point of care and concentrated in a handful of large EHR vendors and the health systems that run them. Its strength is clinical depth — labs, vitals, medications, notes, diagnoses. Its weakness is fragmentation: a patient seen across multiple systems leaves a record split across multiple silos, and unstructured notes require heavy processing to become analyzable.

Claims data. Generated by the billing and reimbursement process. Claims are the workhorse of real-world analytics because they follow the money across providers, giving a more continuous longitudinal view of where and when care happened. Industry analyses consistently rank claims as the single largest real-world data category by usage share, precisely because of that cross-provider continuity. The trade-off: claims describe what was billed, not always what was clinically true, and they thin out on outcomes and detail.

Registries. Disease- or device-specific datasets, often curated by clinical societies or sponsors. High quality and well-defined within scope, but narrow by design.

Academic and public datasets. De-identified research cohorts and government datasets. Invaluable for benchmarking and method development; typically smaller, older, or narrower than commercial sources, and governed by their own data-use agreements.

Synthetic data. Machine-generated records produced by GANs, diffusion models, large language models, and related techniques to mimic the statistical shape of real data without exposing real patients. The category is real and growing — by some estimates the synthetic-data market crossed the multi-billion-dollar mark around 2026 — and it is genuinely useful for privacy-preserving prototyping, augmentation of rare classes, and software testing.

Who owns it versus who sells it

Ownership and distribution are not the same thing, and conflating them is where buyers get burned.

The original custodians — health systems, providers, payers, labs — generate and hold the source records. Above them sits a layer of aggregators and platforms that license, normalize, link, and resell de-identified data, increasingly through governed analytics environments rather than raw file transfers. That platform layer has been consolidating: in early 2026, for example, a major RWD platform announced the acquisition of a large claims-and-clinical data subsidiary, continuing a multi-year trend of roll-ups that concentrate distribution.

The governance shift matters as much as the consolidation. The market is moving away from "send me the file" toward tokenized linkage (privacy-preserving identifiers that join a patient's records across sources without exposing identity) and in-place analytics (you bring your model to the data, inside a controlled enclave). This protects patients and reduces leakage risk — but it also constrains how data can be reshaped, which becomes a live issue for AI training.

Where AI changes the demand curve

For analytics and real-world evidence, governed access to RWD has become standard, and regulators have leaned in. The FDA's real-world evidence program and guidance on using EHR and medical claims data for regulatory decisions, together with the international harmonization of ICH E6(R3) — which formally recognizes pragmatic trials, registry-based studies, and RWD — have legitimized real-world data as evidence when it is fit for purpose.

> Using real-world data to support a regulatory submission carries specific fit-for-purpose, provenance, and quality requirements. Treat regulatory acceptance as a question for your regulatory team, not a given.

AI model development asks something different. A query-the-enclave analytics workflow optimizes for governed access to answer a defined question. Training and evaluating models optimizes for volume, coverage, label quality, structure, and the right to compute over the data at scale. Those are not the same requirements, and the same dataset can be excellent for one and poor for the other.

This is also where synthetic data hits its ceiling. The research consensus through 2026 is consistent: synthetic data is a strong privacy-preserving tool, but it can miss rare pathologies, amplify demographic bias, and let large generators hallucinate clinical facts. It is an augmentation, not a substitute for grounding — which is precisely why the field keeps circling back to verified real records as the anchor.

The emerging gap: pre-training-grade clinical data

Put the pieces together and a gap appears. Claims are broad but clinically shallow. EHR is deep but fragmented and locked in silos. Registries and academic sets are clean but narrow. Synthetic data is flexible but ungrounded. Governed enclaves are great for asking questions and harder for building models.

What model builders increasingly need is a distinct asset: de-identified, coded, longitudinal clinical data that is structured for machine consumption, broad enough to cover real-world variation, consistent enough to trust as a label source, and licensable under terms that actually permit model development. Call it pre-training-grade data — the difference between data you can query and data you can build on. As of 2026, this is the least-served corner of the medical data market.

Key takeaways

• The medical data market is a stack of distinct asset classes — EHR, claims, registries, academic, and synthetic — not one undifferentiated pool.
• Claims data dominates real-world analytics because it tracks care continuously across providers; EHR data is deeper but fragmented.
• Ownership (custodians) and distribution (aggregating platforms) are separate layers, and the platform layer is consolidating while shifting toward tokenized linkage and in-place analytics.
• Regulators now accept fit-for-purpose real-world data as evidence, but AI training has different requirements than analytics: volume, coverage, structure, label quality, and the right to compute.
• Synthetic data is a useful privacy-preserving augmentation, not a grounded substitute — leaving a real gap for pre-training-grade clinical data.

Where Prometheus fits

Prometheus Bio sits deliberately in that gap. We own, refine, and license de-identified, coded, longitudinal clinical data as ground truth — built for the requirements that AI labs and pharma teams actually have, not repurposed from a billing or analytics workflow. If the rest of the market is optimized for asking questions, our focus is on the data you build on.